Learn More About The Cancer Treatment Centers Of America

Posted on November 19, 2017

Allscripts and Nanthealth have partnered with Cancer Treatment Centers Of America to expand their already successful oncology department says, PRN Newswire. Thousands of cancer patients reach out to their network as a caring medical alternative to traditional cancer treatment. Their oncologists have been able to find evidence based treatment programs. Their new workflow program through their partnership with Nanthealth will help more patients get personalized care through a seamless method. You have a professional team of associates work diligently towards you getting better and live a better life when you’ve been diagnosed with cancer.

Get appropriate treatment options for your needs. They offer their clients safe and efficient treatment. You can leave a healthy longer life with accurate oncology reports that tell physicians exactly what you need. Choose to live a full life and go through the remission of cancEr with less worries of the cancer coming back. Their nontraditional method of treating cancer has been a preferred method for thousands of patients nationwide. They give you a comparison for other sources of cancer treatment. Their team of dedicated professionals is there to put the life of their patients first. Get the life you should be living with your battle with cancer.

You’re invited to visit one of their locations nationwide to find out your options for treatment. They also offer a unique website with more details and information on their success stories at Cancer Treatment Centers Of America. Live well with the top traditional cancer treatment alternative nationwide.

Visit More : http://www.myctca.com

Eric Lefkofsky, the Outstanding Entrepreneur that Cares for your Health

Posted on November 19, 2017

Health remains the most vital sector in all societies and anything that affects it means that the nation, in general, has a problem. In America, the issue is not any different. Over the recent years, health care has continuously shot up in the sense that if one compares its costs from way back in 1996 to present, the cost of health care is very high.

Some of the reasons that are found to be the cause include; continuous growth of population and aging, that is, more people are getting older, and this means that they need care and not just any attention but a special one. This means areas like homes for the aged have to be built and of course, this means finances. The high prices of healthcare are what leads to high spending by the patients when it comes to receiving care of any sort. The more common a disease is likely to affect people, the more its spending is escalated. For instance, numerous people have diabetes in various parts of the country, and a lot of money is spent on buying medicines. For back pain, neck pain, and others that affect so many are also costly. Although in this case, it’s not about drugs, and the care such patients are given like massage and other pain relieving procedures, which in turn becomes expensive.

Despite the high costs, all hope is not lost as organizations like Lefkofsky foundation are of excellent health. Out of the need for health care, Eric Lefkofsky who is the president of the foundation merged his Startup, Tempus, with Northwestern University’ Cancer center. After that, the CEO hired Kevin White, who is the top researcher in genetics thereby his work comes in handy to cancer patients noting that cancer is one of the worst diseases ever. More so, the prices of genetic sequencing have reduced.

Eric Lefkofsky is the CEO of Tempus has helped a lot in the health sector. He is an entrepreneur, his numerous involvements in different ventures in the society is of help. Also, he is a man with a big heart where he is helping the community via ventures like Lefkofsky foundation, which also considers children.

To Learn More Click Here

Clay Siegall is Changing Lives of Cancer Patients

Posted on October 16, 2017

Dr. Clay Siegall is one of the most successful biotechnologists in the world. At the moment, the scientist is based in the United States, and he is working hard to change the lives of numerous people who are living with the dangerous cancer disease. At the moment, Clay Siegall is working as the president for one of the leading biotechnology companies in the country, known as Seattle Genetics. The scientist is also the chairman of the institution. Seattle Genetics is an institution that specializes in the creating of therapies that cure diseases such as cancer. Most of the drugs developed by the private company have helped many people who are living with various conditions.

Clay Siegall has a rich educational background. According to his portfolio, the businessman went for his studies at the famous University of Maryland where he got his first degree in zoology. After some time, the scientist decided to go back to school and study genetics from the prestigious George Washington University.

As the founder and leader of the biotechnology company, Clay Siegall has been doing his best to ensure that customers living with cancer get the cure that they need. The company has been doing well, and it has been recognized in several platforms. The company recently released the first drug, and it has been doing well. According to Clay Siegall, the drug is already being used in over sixty nations, from all over the world. The people who have used the powerful drug have been cured, and more of them are living a healthy life.

In the modern world, many people are living with the cancer disease. The medication available in most countries causes serious side effects to the cancer patients, making things very difficult. People who use the traditional cancer treatment options die from the effects of the medications. Clay Siegall watched as one of his close relatives died from the condition. This motivated him to go to school and learn how to assist the people who are living with cancer. Since childhood, the businessman wanted to become a medical doctor, and this made things easier for him. Clay has changed the lives of so many people in the world.

Mikhail Blagosklonny devotion to Acquiring an Effective Cancer Treatment

Posted on July 28, 2017

Mikhail Blagosklonny is an oncology professor at the Roswell Park Cancer Institution. He is a scientist and specializes in cancer and aging. He has an M.D. in internal medicine from the First Pavlov State Medical University, St. Petersburg. He advanced his education in the same university and attained a PhD in experimental medicine and cardiology.In 2002, Mikhail was appointed as the associate professor of medicine at the New York Medical College situated in Valhalla, New York. He was hired by the Ordway Research Institute in Albany, New York, as a senior scientist. In 2009, Mikhail became a professor of oncology at the renowned Roswell Park Cancer Institute. He had gained vast knowledge and experience in his previous workplaces, and this made him an excellent professor. Mikhail based his research on biogerontology (the underlying mechanism of aging), cancer, anti-aging drugs, as well as cancer therapies which guard the healthy body cells against destruction.

Mikhail also serves as the editor-in-chief of Oncotarget, and Aging. He is not only the founder editor of Cell Cycle but also the editor-in-chief. He is an associate editor of cancer therapy and biology. Mikhail is on the editorial panel of Cell Death and Differentiation. He released a proposition concerning the potential role of TOR signalling in cancer and aging. In the hypothesis, Mikhail proposed the utilization of Rapamycin as a possible treatment for life extension.Mikhail gives insight into how rejuvenation of cells helps to reduce the incidences of cancer in aged people. Mikhail defines aging as the progressive growth of cells. Rapamycin is a drug used to treat cancer. Mikhail is one of the enthusiastic advocates for Rapamycin in the longevity research. Mikhail argues that the usage of Rapamycin can minimize the aging process in human beings as it strengthens the body’s immunity. Over the years, scientists have provided several results on the use of anti-aging products in cancer management.

Most of Mikhail studies range from clinical investigations to molecular and cellular biology. The studies include ontogenesis, apoptosis, anti-cancer therapeutics, signal transduction, tumor suppressors, cell cycle, mitosis, and drug resistance for normal body cells. Mikhail writes about aging hyperfunction theory, chemotherapeutic, and cyclotherapy engineering. He has published more than 300 book chapters, research articles and reviews. Mikhail Blagosklonny has used approximately 25,000 citations, therefore, has an h-index of 83. Also, he is an associate editor of the American Journal of Pathology, PLOS ONE, and the International Journal of Cancer.Mikhail Blagosklonny is famous for his passion in oncology. He firmly believes that controlling aging and cancer is achievable. According to Mikhail, cancer can be cured, which is why he recommends the use of Rapamycin. Mikhail’s devotion to his work has brought great achievements in his field of specialization. He is one of the greatest oncologist researchers in the world today. His achievements are attributed to his love for humanity and his vision for a disease free society.It is clear that Mikhail is an accomplished Scientist, professor of oncology and medicine, and physician. He has risen through ranks and holds several top-notch appointments.

Mikhail Blagosklonny’s Contributions to Oncology and Anti-Aging

Posted on July 23, 2017

After extensive research, Mikhail Blagosklonny is convinced that aging can be prevented. With proper treatment, people can live longer. He proposed the use of rapalogs like rapamycin to prevent aging as well as the diseases that result from aging. Everolimus (RAD001) can be used to boost immunity. This research is helpful to the youth as well as the old people. It will help people to live long and healthy lives and aging will not be dreaded anymore. According to Nir Barzilai, the success and use of the “fountain of youth drug” will be a milestone in research.

Rapamune could be used to treat age-related diseases like Alzheimer’s and osteoporosis. The drug was already available in the market for use in the treatment of autoimmune diseases, cancer, and cardiovascular diseases. Rapamycin could work better as a preventive rather than a curative drug for aging and age-related diseases. The drug has been in use to help patients who are undergoing transplants. It reduces the chances of the patient’s body rejecting foreign organs. This makes the drug suitable for everyday use even for slowing down the aging process. Read more about Mikhail at LinkedIn

According to the research by Mikhail Blagosklonny, the treatment would make an adult have the immunity of a child. The treatments will reduce the number of people who die because of age. Damaged molecules and selfish mitochondria among several other factors cause aging.

Mikhail Blagosklonny has also done a lot of research in oncology. Some of the things that he has researched on include anticancer therapeutics, tumor suppressors, mitosis, therapies that prevent healthy cells from being affected by cancer and apoptosis. Through his research, he realized that cancer can be cured. Rapamycin, which was proposed to treat aging, could also cure cancer. His commitment to discovering solutions to problems in oncology and aging has made him an expert in the fields.

Mikhail Blagosklonny attended the First Pavlov State Medical University of St. Petersburg. There he got his MD in Internal Medicine and his Ph.D. in Experimental Medicine and Cardiology. He has been at Roswell Park Cancer Institute as an oncology professor since 2009. Before then, he worked at the New York Medical College as an associate professor. He was also a senior scientist at the Ordway Research Institute. His research and experience make Mikhail an excellent professor.

Mikhail Blagosklonny also writes a lot about aging and oncology. He shares his finding with other people who have similar interests. Cell Cycle and Oncotarget have him as the editor-in-chief. In Cancer Biology and Therapy, he serves as an associate editor. Mikhail sits on the editorial board of Cell Death and Differentiation. He is regarded as one of the people who strongly believe in the use of Rapamycin. Visit ResearchGate to know more about Mikhail’s latest work.

The hyperactive function theory, chemotherapeutic engineering, and cyclotherapy are some of the subjects that Mikhail has written extensively about them. He has more than 300 publications including books, reviews, and research articles. According to Mikhail Blagosklonny, his motivation comes from his dream to eradicate diseases.

How Eric Lefkofsky’s Colossal Genomic Database Will Benefit Cancer Patients

Posted on July 23, 2017

While Eric Lefkofsky graduated from the University of Michigan with a law degree, his real talent is being an entrepreneur who thrives on risk. In fact, Lefkofsky’s latest venture is genomics company, even though he has no medical background.

As the co-founder and CEO at Tempus, Lefkofsky oversees the compilation of a colossal database that physicians can use to personalize cancer therapies. Actually, Tempus is based on utilizing big data, as were Lefkofsky’s previous ventures, therefore it isn’t so unusual that he would compile gene-sequencing test results. With numerous Ph.D.s working at Tempus, Lefkofsky’s role is to bring the data together and make it simple for physicians to utilize. Tempus does this by partnering with hospitals that contribute data in return for software, which doctors will use to compare their cancer patient’s genetic profile to other profiles already in the database, in order to determine which treatments have been successful in similar cases.

In addition to co-founding Tempus, Lefkofsky also co-founded Lightbank, a venture fund that invests in diverse companies, especially startups employing disruptive technologies. Lefkofsky wrote a book titled Accelerated Disruption: Understanding the True Speed of Innovation, where he explains why businesses utilizing disruptive tactics often succeed where others fail. In his book, Lefkofsky warns potential entrepreneurs not to hesitate, because with technology, a competitor could easily overtake them and get their idea to market first.

A Chicago resident, Lefkofsky is active in his community; he sits on the boards of the Art Institute of Chicago, the Children’s Memorial Hospital and The Museum of Science and Industry. Adjunct Professor Eric Lefkofsky also teaches course on entrepreneurship at the University of Chicago Booth School of Business.

If anyone knows about entrepreneurship, it is Lefkofsky, who co-founded InnerWorkings, Echo Global Logistics, MediaBank and ThePoint.com. In his spare time, Lefkofsky oversees the Lefkofsky Foundation, which supports charitable causes around the world.

About Eric Lefkofsky: www.tempus.com/about-us/

Eric Lefkofsky, Tempus Co-Founder and CEO

Posted on May 10, 2017

Tempus, a genomic data company co-founded by Eric Lefkofsky gives physicians at the University of Chicago data to facilitate better treatment of their breast cancer patients. The Chicago-based Tempus announced a joint partnership with the University of Chicago Medicine. It will make available molecular sequencing and analysis to breast cancer specialists at the university to enable them to create individual treatments plans for their patients. Tempus offers to evaluate data for 1,000 breast cancer patients to assist the university physicians and researchers find out patterns to determine how patients will respond to treatment.

The purpose of molecular sequencing and analysis data will, eventually, lead to effective treatment and improved patients recovery results. “Although breast cancer is among the most common cancers, there is relatively little accessible data on the millions of patients who have battled the disease,” Dr. OlufunmilayoOlopade, professor and dean stated. “This forces too many physicians to make treatment decisions without the benefit of highly specific genetic information that could help them make better informed and precisely targeted decisions,” she added.

Mr Eric is an accomplished entrepreneur, investor, a philanthropist and an author. He is a Co-Founder and CEO of Tempus, a data company that provides molecular sequencing and analysis data technology use for the treatment of cancer. He is a founding partner of Lightbank, a company that provides venture capital investment in disruptive technology; the co-founder and Chairman of Groupon, a worldwide e-commerce marketplace; a co-founder of Uptake Technologies, a top predictive analytics platform for worldwide major industries; Mediaocean Company, a major provider of integrated media procurement technology; InnerWorkings Inc. a top provider of managed print and publicity solutions; and Echo Global Logistics company, a tech-enabled transportation and logistics subcontracting firm. He and his wife, Liz are co-chairs of Lefkofsky Family Foundation that advocates for high-impact community initiatives to improve lives in their communities. He chairs the Board of Trustees of Chicago’s Steppenwolf Theater; he is an adjunct professor at the University of Chicago and an author. He attended University of Michigan and hold a Juris Doctor (JD) degree from University of Michigan Law School.